HCW Biologics Inc. (NasdaqCM: HCWB)
Health Care · Biotechnology · US
$2.11
-3.21% today · -93.5% 1Y
HCW Biologics Inc. (NasdaqCM: HCWB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.00M and employs 35 people.
Over the last twelve months the share price has lost 93.5%, trading between 1.50 and 44.10.
Tweenvest scores HCW Biologics Inc. across four factors: quality 12/100, value 49/100. Its strongest factor is value.
HCWB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.00M
- Revenue (TTM)
- $6.72M
- P/E
- —
- EPS
- -27.18
- Dividend yield
- —
- Beta (5Y)
- 2.36
- 52-week high
- $44.10
- 52-week low
- $1.50
- Avg volume (3M)
- —
- Shares outstanding
- 1.84M
- Employees
- 35
- Next earnings
- —
About HCW Biologics Inc.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
- Founded
- 2018
- Listed since
- Jul 20, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.14 | +0.45% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.01 | -1.42% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.